Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
:MLYS
MLYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.24 - $18.29
Previous CloseN/A
Volume137.34K
Average Volume (3M)919.74K
Market Cap
$712.65M
Enterprise Value$339.66M
Total Cash (Recent Filing)$114.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.89
Next Earnings
May 19, 2025EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding49,835,636
10 Day Avg. Volume2,084,237
30 Day Avg. Volume919,741
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$32.00Price Target Upside123.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessMineralys Therapeutics shared positive topline data from its two pivotal trials with lorundrostat in hypertension, both meeting or surpassing clinical meaningfulness standards.
Regulatory Approval ProspectsThe safety profile of lorundrostat was acceptable, with manageable hyperkalemic events, supporting regulatory approval prospects.
Bears Say
Market And Competition ChallengesThe heavily genericized hypertension market means that marketing and payer-related challenges are anticipated for Mineralys Therapeutics.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MLYS FAQ
What was Mineralys Therapeutics, Inc.’s price range in the past 12 months?
Mineralys Therapeutics, Inc. lowest stock price was $8.24 and its highest was $18.29 in the past 12 months.
What is Mineralys Therapeutics, Inc.’s market cap?
Mineralys Therapeutics, Inc.’s market cap is $712.65M.
When is Mineralys Therapeutics, Inc.’s upcoming earnings report date?
Mineralys Therapeutics, Inc.’s upcoming earnings report date is May 19, 2025 which is in 67 days.
How were Mineralys Therapeutics, Inc.’s earnings last quarter?
Mineralys Therapeutics, Inc. released its earnings results on Feb 12, 2025. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.077 by $0.097.
Is Mineralys Therapeutics, Inc. overvalued?
According to Wall Street analysts Mineralys Therapeutics, Inc.’s price is currently Undervalued.
Does Mineralys Therapeutics, Inc. pay dividends?
Mineralys Therapeutics, Inc. does not currently pay dividends.
What is Mineralys Therapeutics, Inc.’s EPS estimate?
Mineralys Therapeutics, Inc.’s EPS estimate is -1.03.
How many shares outstanding does Mineralys Therapeutics, Inc. have?
Mineralys Therapeutics, Inc. has 49,835,636 shares outstanding.
What happened to Mineralys Therapeutics, Inc.’s price movement after its last earnings report?
Mineralys Therapeutics, Inc. reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.077. Following the earnings report the stock price went up 10.041%.
Which hedge fund is a major shareholder of Mineralys Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MLYS
---
Mineralys Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.00 (123.78% Upside)
$32.00 (123.78% Upside)
Blogger Sentiment
Bullish
MLYS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 12.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.84%
12-Months-Change
Fundamentals
Return on Equity
-82.24%
Trailing 12-Months
Asset Growth
-18.17%
Trailing 12-Months
Company Description
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing innovative therapies for the treatment of cardiovascular and renal diseases. The company operates within the healthcare sector and specializes in the research and development of novel therapeutic solutions aimed at addressing unmet medical needs in these areas. Mineralys’ core product pipeline is centered around the development of targeted treatments that leverage its expertise in mineralocorticoid receptor biology.
---
MLYS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook overall with strong clinical progress and a solid financial position, despite increased R&D expenses and net loss. The company remains optimistic about upcoming data readouts and market potential for lorundrostat.Read More>---
MLYS Stock 12 Month Forecast
Average Price Target
$32.00
▲(123.78% Upside)
Technical Analysis
Ardelyx
―
Amphastar Pharmaceuticals
―
Rocket Pharmaceuticals
―
Kiniksa Pharmaceuticals
―
Kezar Life Sciences
―
Best Analysts Covering MLYS
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+23.27%
reiterated a buy rating 3 days ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.27% per trade.
---